MMH-MAP(MMH-MAP) - 在研适应症：缺血性卒中_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Prospecta

靶点-

作用机制-

治疗领域

神经系统疾病心血管疾病

在研适应症

缺血性卒中

非在研适应症

轻度认知障碍

原研机构

OOO NPF Materia Medica Holding

在研机构

OOO NPF Materia Medica Holding

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 MMH-MAP 相关的临床试验

EUCTR2021-002366-41-IT / Unknown status临床2期IIT

Phase II, multicenter, randomized, open-label study with MAP +/- denosumab regimen for the treatment of patients with metastatic osteosarcoma - AIEOP-ISG OsM+

开始日期2021-09-28

申办/合作机构

Associazione Italiana Di Oncologia Medica

NCT04295681 / Completed临床3期

A Multicenter, Double-blind, Randomized, Parallel Group Placebo-controlled Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders in Patients With Ischemic Stroke in the Carotid Arteries

The clinical trial to valuate efficacy and safety of MMH-MAP in the treatment of cognitive disorders in patients with ischemic stroke in the carotid arteries.

开始日期2019-12-12

申办/合作机构

OOO NPF Materia Medica Holding

NCT03815292 / Completed临床3期

Multicenter Double-blind Placebo-controlled Randomized Parallel-group Clinical Study of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Subjects in Early Rehabilitation Period of Ischemic Stroke

The purpose of this study is:
to evaluate efficacy of MMH-MAP in the treatment of mild cognitive impairment in subjects in early rehabilitation period of ischemic stroke
to evaluate safety of MMH-MAP in the treatment of mild cognitive impairment in subjects in early rehabilitation period of ischemic stroke

开始日期2018-10-19

申办/合作机构

OOO NPF Materia Medica Holding

100 项与 MMH-MAP 相关的临床结果

登录后查看更多信息

100 项与 MMH-MAP 相关的转化医学

登录后查看更多信息

100 项与 MMH-MAP 相关的专利（医药）

登录后查看更多信息

47

项与 MMH-MAP 相关的文献（医药）

2024-05-02·ChemMedChem

Effective Anticancer Potential of a New Sulfonamide as a Carbonic Anhydrase IX Inhibitor Against Aggressive Tumors

Article

作者: Durgun, Mustafa ; Giovannuzzi, Simone ; Supuran, Claudiu T ; Yuksekdag, Ozgür ; Koyuncu, Ismail ; Güler, Eray Metin ; Temiz, Ebru

AbstractThis study examines efficiency of a newly synthesized sulfonamide derivative 2‐bromo‐N‐(4‐sulfamoylphenyl)propanamide (MMH‐1) on the inhibition of Carbonic Anhydrase IX (CA IX), which is overexpressed in many solid tumors including breast cancer. The inhibitory potential of MMH‐1 compound against its four major isoforms, including cytosolic isoforms hCA I and II, as well as tumor‐associated membrane‐bound isoforms hCA IX and XII, was evaluated. To this context, the cytotoxic effect of MMH‐1 on cancer and normal cells was tested and found to selectively affect MDA‐MB‐231 cells. MMH‐1 reduced cell proliferation by holding cells in the G0/G1 phase (72 %) and slowed the cells′ wound healing capacity. MMH‐1 inhibited CA IX under both hypoxic and normoxic conditions and altered the morphology of triple negative breast cancer cells. In MDA‐MB‐231 cells, inhibition of CA IX was accompanied by a decrease in extracellular pH acidity (7.2), disruption of mitochondrial membrane integrity (80 %), an increase in reactive oxygen levels (25 %), and the triggering of apoptosis (40 %). In addition, the caspase cascade (CASP‐3, ‐8, ‐9) was activated in MDA‐MB‐231 cells, triggering both the extrinsic and intrinsic apoptotic pathways. The expression of pro‐apoptotic regulatory proteins (Bad, Bax, Bid, Bim, Cyt‐c, Fas, FasL, TNF‐a, TNF‐R1, HTRA, SMAC, Casp‐3, ‐8, P21, P27, and P53) was increased, while the expression of anti‐apoptotic proteins, apoptosis inhibitor proteins (IAPs), and heat shock proteins (HSPs) (Bcl‐2, Bcl‐w, cIAP‐2, HSP27, HSP60, HSP70, Survivin, Livin, and XIAP) was decreased. These results propose that the MMH‐1 compound could triggers apoptosis in MDA‐MB‐231 cells via the pH/MMP/ROS pathway through the inhibition of CA IX. This compound is thought to have high potential and promising anticancer properties in the treatment of aggressive tumors.

2022-11-01·Asian Journal of Surgery3区 · 医学

Outcome of a modified Park's submucosal hemorrhoidectomy versus Milligan-Morgan for grade III-IV circumferential prolapsed hemorrhoids

3区 · 医学

ArticleOA

作者: Zhang, Tongcheng ; Sun, Wei ; Song, Xianqing ; Bao, Yintong ; Tu, Jinjin

BACKGROUNDThis prospective randomized controlled study compared the short- and long-term efficacy and advantages of modified Park's submucosal over Milligan-Morgan hemorrhoidectomy (MMH) in the treatment of grade III and IV circumferential prolapsed hemorrhoids (CPH).METHODSA total of 186 consecutive patients with grade III or IV CPH were enrolled. The patients were randomized to MPSH (n = 93) or MMH (n = 93) treatment groups. Patient data included demographics, clinical characteristics, surgical parameters, underlying or arising complications, and CPH recurrence. The patients were closely followed up for at least 24 months.RESULTSThe patient demographic data and clinical parameters were comparable in the two groups (P > 0.05). MPSH took significantly longer operative time (P < 0.05). Although there was no significant difference in mean postoperative pain between the two groups at days 3 and 14, pain at day 7 was significantly more frequent and severe in the MMH group (P < 0.05). There were no significant group differences in postoperative bleeding, intraoperative blood loss, or development of anal stenosis (P > 0.05). However, the cumulative relapse-free rate was substantially higher in the MPSH group (P < 0.05).CONCLUSIONMPSH and MMH are both practical and safe techniques for treating grade III and IV CPH disease. However, MPSH is safer, easier, and faster to perform and is associated with fewer recurrences within 24 months of surgery. Additional clinical studies are needed to validate these conclusions.

2022-06-24·International Journal of Analytical Chemistry

Preparation and Sound Insulation Performance of Polystyrene Building Flame Retardant and Thermal Insulation Building Materials

Article

作者: Guo, Qiulan

In this study, magnesium hydroxide (MH) was modified by sodium dodecylbenzene sulfonate (SDBS) to prepare modified magnesium hydroxide (MMH) flame retardant, which was mixed with polystyrene (PS) to obtain flame retardant PS composite plate. The micromorphology, mechanical properties, thermal stability, and flame retardancy of flame retardant PS composite plate were analyzed. The experimental results show that MMH is well dispersed in PS matrix, PS-MMH-3 has the best tensile strength and elongation at break, the limit oxygen index (LOI) is 44.3% higher than that of pure PS, and the combustion rate is slow, indicating that PS-MMH-3 has good flame retardant properties.

100 项与 MMH-MAP 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
缺血性卒中	临床3期	俄罗斯	OOO NPF Materia Medica Holding	2018-10-19
轻度认知障碍	临床2期	俄罗斯	OOO NPF Materia Medica Holding	2018-10-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04295681 (CTgov)	临床3期	认知功能障碍 \| 缺血性卒中	246	MMH-MAP (MMH-MAP)	鏇艱選簾憲鑰夢夢鏇鬱(觸廠繭壓築壓築膚選齋) = 膚襯鏇製憲構顧簾壓簾廠糧膚蓋獵鏇醖夢窪鹽 (襯積淵夢衊顧築膚鏇簾, 觸廠積鑰遞築願鹽醖鏇 ~ 窪壓積願淵築餘膚淵壓) 更多	-	2024-10-28
				Placebo (Placebo)	鏇艱選簾憲鑰夢夢鏇鬱(觸廠繭壓築壓築膚選齋) = 顧製網鏇網積鹽襯膚範廠糧膚蓋獵鏇醖夢窪鹽 (襯積淵夢衊顧築膚鏇簾, 鹽夢遞憲餘鏇獵網憲網 ~ 廠顧觸願憲鹽觸獵衊齋) 更多
NCT03815292 (CTgov)	临床3期	缺血性卒中 \| 轻度认知障碍	276	MMH-MAP (MMH-MAP)	鬱鏇膚襯淵積衊獵鑰積(衊蓋範願廠蓋構獵衊願) = 鑰遞淵鬱鏇範網築選淵構範選艱淵齋衊廠築襯 (網顧範鹹鹽願製餘構膚, 艱積構觸構積鑰觸鬱襯 ~ 築構觸憲範淵構衊淵製) 更多	-	2021-02-23
				Placebo (Placebo)	鬱鏇膚襯淵積衊獵鑰積(衊蓋範願廠蓋構獵衊願) = 築餘網築積製鹽齋壓積構範選艱淵齋衊廠築襯 (網顧範鹹鹽願製餘構膚, 窪製顧鑰鏇選鑰餘衊夢 ~ 願簾衊夢鏇艱夢顧構廠) 更多